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Objective: To undertake an economic analysis of the Take Charge intervention as part of the 
Taking Charge after Stroke (TaCAS) study.
Design: An open, parallel-group, randomised trial comparing active and control interventions 
with blinded outcome assessment
Setting: Community
Participants: Adults (n = 400) discharged to community, non-institutional living following 
acute stroke.
Interventions: The Take Charge intervention, a strengths based, self-directed rehabilitation 
intervention, in two doses (one or two sessions), and a control intervention (no Take Charge 
sessions).
Measures: The cost per quality-adjusted life year (QALY) saved for the period between 
randomisation (always post hospital discharge) and 12 months following acute stroke.  QALYs 
were calculated from the EuroQol-5D-5L. Costs of stroke-related and non-health care were 
obtained by questionnaire, hospital records, and the New Zealand Ministry of Health.
Results: One-year post hospital discharge cost of care was mean (95%CI) $US4,706 (3,758 to 
6,014) for the Take Charge intervention group and $6,118 (4,350 to 8,005) for control, mean 
(95%CI) difference $-1,412 (-3,553 to +729). Health utility scores were mean (95%CI) 0.75 
(0.73 to 0.77) for Take Charge and 0.71 (0.67 to 0.75) for control, mean (95%CI) difference 
0.04 (0.0 to 0.08). Cost per QALY gained for the Take Charge intervention was $US-35,296 
(=£-25,524, €-30,019).  Sensitivity analyses confirm Take Charge is cost-effective, even at a 
very low willingness-to-pay threshold. With a threshold of $US5,000 per QALY, the 
probability that Take Charge is cost-effective is 99%. 
































































Conclusion: Take Charge is cost-effective and probably cost saving.


































































There are few proven effective interventions for people with stroke, once they have been 
discharged from hospital.[1-3]  We have recently shown that the Take Charge intervention – 
a low-cost, strengths based, ‘talking therapy’ intervention in the early phase of community 
rehabilitation after stroke – was effective in a second randomised controlled trial, improving 
physical health and reducing dependence at 12 months after stroke.[4]  In an individual 
patient meta-analysis combining the two Take Charge studies [4, 5] (n=572), the number 
needed to treat was eight, for one more person to be independent (modified Rankin Score 0-
2) at 12 months.[4]  
The purpose of this study was to undertake an economic analysis of the Take Charge 
intervention, performing a pre-specified 1-year prospective evaluation of utility outcomes and 
costs among participants in the Taking Charge after Stroke (TaCAS) trial. We evaluated the 
cost-utility of the Take Charge intervention compared to a control intervention, in addition to 
usual rehabilitation care, for patients recovering from stroke.  We used a 12-month time 
horizon and the analysis was from the perspective of the District Health Board, the major 
source of healthcare funding in New Zealand.
Methods
The trial is registered with the Australia New Zealand Clinical Trials Registry 
ACTRN12615001163594. The study protocol was approved by the New Zealand Health and 
Disability Ethics Committee. Written informed consent was obtained from all participants. 
The trial was funded by a grant from the Health Research Council of New Zealand (15/297).  
Participants were enrolled between October 2015 and August 2017. The full study protocol 
and results of the Taking Charge after Stroke trial, containing a full description of the study 
methods, are published elsewhere [4, 6]. 
































































In brief, this was a prospective open-label randomised controlled trial comparing the Take 
Charge intervention to a control intervention with masked endpoint assessment.  To test 
whether outcomes improved in relation to dose of the intervention, participants were 
randomised into three groups: zero Take Charge sessions (control), one, or two Take Charge 
sessions six weeks apart. Participants were adults diagnosed with acute stroke, discharged to 
live in the community in non-institutional care, no more than 16 weeks following their stroke.  
The trial was conducted in seven centres in New Zealand, four tertiary and three non-tertiary 
centres, serving a catchment population of around 2.4 million people, about half the 
population of New Zealand.[7] All participants received evidence-based acute inpatient 
stroke care and early stroke rehabilitation care along with inpatient and community stroke 
rehabilitation as indicated, that was unaffected by study allocation. 
Participants were randomised into the three arms of the study (control, one session, two 
sessions) in a 1:1:1 ratio. Allocations were concealed in sequentially numbered, opaque, 
sealed envelopes, and once opened either the control or active intervention proceeded at the 
same visit. Envelopes were prepared for each centre in blocks of 18 by the study statistician 
using computer-generated random numbers. All baseline and 12-month assessments were 
collected face-to-face apart from five (1.3%) 12-month assessments made by telephone. Six-
month and 12-month assessments were collected blind to treatment allocation. Six-month 
assessments were made by postal or electronic questionnaire with a small number of 
assessments (6%) by telephone.
Participants randomised to control were given written educational material about stroke 
produced by the Stroke Foundation of New Zealand, covering common issues following 
stroke and risk factor management.[8]   Take Charge is a strengths based ‘talking therapy’ 
and aims to encourage a sense of purpose, autonomy, mastery and connectedness with others 
































































[4].  The intervention and training manual can be downloaded at no cost from 
www.mrinz.ac.nz/programmes/stroke .
We undertook a whole-system approach to evaluate the annual costs and benefits, to utilize 
the detailed Take Charge dataset with minimal assumptions, using a 12-month horizon. 
The direct cost of the Take Charge intervention was set at $US70 per session for this 
analysis.  An average session takes between 45 and 60 minutes, although there was no 
prescribed time limit. The cost per session is based on 1.5 hours’ time including travel for a 
New Zealand nurse on a middle-grade salary and an allowance for travel costs. Although 
health professionals (nurses and physiotherapists) were used as facilitators for this study, a 
health background is not essential for this intervention. [5]  
All original costs were in New Zealand (NZ) dollars. For this report, these have been 
converted into United States (US) dollars valued in 2018 (NZ(2018)$1 = US(2018)$0.7017). 
[9] Costs are from the perspective of the District Health Board, the major source of healthcare 
funding in New Zealand. We did not apply discounting because the time horizon of the 
analysis was less than one year.
Cost of healthcare was determined using information from a variety of sources, including 
direct medical costs for hospital readmission from New Zealand Ministry of Health data for 
individual patients [10] and follow-up resource use for outpatient evaluations at six and 12 
months by self-reported questionnaire from the participants.  The cost of the initial stroke 
admission was excluded: costs were determined from the time of randomisation, which was 
always after hospital discharge.
The cost of hospital readmission was assessed from hospital reimbursements from the 
Ministry of Health.[11]  Stroke related readmission were confirmed by International 
Classification of Disease (ICD)10 codes I60-69.  Cost of hospital readmission were 
































































determined using Weighted Inlier Equivalent Separation (WIES) for all public hospitals by 
the Ministry of Health.  The national price for the financial year 2017/2018 per WIES was 
$US3,453.18 ($NZ4,921.16) [12]. 
The cost of outpatient services was determined using a resource-based costing approach that 
measures the inputs required to deliver outpatient services (e.g., deliver the service, time 
required to coordinate the care with other providers etc.) and then applying market prices to 
each of these resources (e.g., cost per hour for the therapist). This provides an estimate not 
only of the net costs associated with the intervention but also the cost to other organizations 
interested in adopting the Take Charge intervention as part of their standard practice. Cost of 
outpatient and rehabilitation care was based on combining frequency of visits identified by 
patients during follow-up assessments with market prices for consultation. Unit prices for 
health and medical consultation was sourced from various sources (see Supplementary table 
A). 
In New Zealand there are two broad categories of aged residential care; Residential Home 
care, where people need a maximum of one-person assistance for functional tasks, or 
Hospital-Level care, where two-person care and/or nursing support is needed. Each of these 
is funded at a different rate and costs were calculated from six-month and 12-month follow-
up visit reports of current accommodation status. The cost of institutional care per week, 
obtained from Ministry of Health mean costs for that care level [11], was multiplied by half 
the number of weeks since the person was last assessed as being in their own home.  
Home Help (non-personal contact such as house cleaning) and Personal Care (washing, 
dressing and other personal care) costs were also obtained from Ministry of Health data 
indexed by the participant’s unique national hospital number. To estimate the cost of these 
services, a resource-based costing approach was used where a common price was applied to 
































































each resource (e.g., cost per hour for home care). All categories were summed together to 
estimate an average cost per person.
Short-term loss of income using a friction cost approach was used,[13] which considers any 
individual absent from paid employment due to temporary illness or disablement will be 
replaced after a specific time. At 6-month and 12-month follow-up participants reported any 
reduction of pay since their stroke. To estimate cost of informal care, individuals were asked 
to report the number of hours of care received by informal carers per week. 
Health utility scores were obtained from responses to the EuroQol-5D-5L (New Zealand 
version) [14]. The EuroQol-5D-5L classifies generic health status on five dimensions: 
mobility, self-care, usual activities, pain or discomfort, and anxiety or depression.  For each 
dimension, the participant is asked to categorize their current health state today in each 
dimension using 1 of 5 descriptions (broadly 1= no problems; 2= slight problem; 3 = 
moderate problems; 4= severe problems; to 5= I am unable). EuroQol-5D-5L valuation does 
not exist for New Zealand and is currently under assessment. Therefore, for this 
predominantly New Zealand European study population, states were valued according to 
published preferences for England [15]. The EuroQol-5D-5L scores were assessed at 
different points in time and transformed into Quality Adjusted Life Years (QALY) using 
complete case analysis and the ‘area under the curve’ method.[16]
The pre-specified primary outcome for this analysis was the cost per quality-adjusted life 
year from randomisation to 12 months following stroke, comparing any Take Charge 
intervention (1 or 2 sessions) with control.  Annual cost per person and QALYs per person 
are presented as means with 95%CI using non-parametric bootstrapping methods. For the 
cost-effectiveness analysis, we identified the differences between costs and QALYs between 
the two arms, dividing the former by the latter to compute an incremental cost-utility ratio 
































































(ICUR) —the incremental cost-utility ratio gives a broad indication of whether spending 
additional money on the Take Charge intervention appears efficient. Uncertainty in the costs 
and effects associated with the Take Charge intervention was explored by an incremental 
cost-utility scatter plot of microsimulations (10,000 replications) by probabilistic modelling 
of increment costs and QALYs on the incremental cost effectiveness plane.[17] Further 
sensitivity analysis was explored with a cost effectiveness acceptability curve. The findings 
are reported in alignment with the Consolidated Health Economic Evaluation Reporting 
Guidelines [18, 19]. SPSS statistics version 22 (IBM SPSS Statistics) and Microsoft Excel 
2016 (Microsoft Corporation 2010) were used for the analysis.
Results 
Between October 2015 and August 2017, 400 participants were randomised to one Take 
Charge session (n = 132), two Take Charge sessions (n = 138) or control intervention (n = 
130) (See Figure 1 for CONSORT diagram). Two participants withdrew consent for follow-
up (one who withdrew after randomisation but before delivery of the intervention, and one 
after completing the intervention but before 6-month follow up, both from the group 
randomised to one Take Charge session). Ten patients (two control, four randomised to one 
Take Charge session, and four randomised to two Take Charge sessions), died during the 
follow up period. All remaining participants (n=388, 97%) were followed up 12 months 
following stroke. 
EuroQol-5D-5L results at 12 months were obtained from 340 participants (control = 109, one 
or two Take Charge sessions = 231), 85% of those initially randomised. Hospital readmission 
and 12-month accommodation status was available for 398 participants (99.5%).  
Baseline demographic and stroke details have been reported in detail previously [4]. The 
study population, as a whole, was elderly (mean (SD) age 72.0 (12.5) years), 234/400 
































































(58.5%) were men, 264/400 (66%) were living with another person, and 386/400 (96.5%) 
were of New Zealand European or ‘other European’ ethnicity.  Māori and Pacific people 
were specifically excluded from this study because of the evidence for benefit of the Take 
Charge intervention for Māori and Pacific people with stroke in a previous randomised 
controlled trial.[5]  Activities of daily living (Barthel Index mean (SD) of 18.9 (2.0)) and 
independence (modified Rankin scale <3 = 310/400 (77.5%)) at randomisation reflected 
inclusion and exclusion criteria favouring recruitment of people with mild and moderate, 
rather than severe stroke.  
Data descriptions and comparisons by randomised treatment for costs and QALYs are shown 
in Table 1. The mean (95%CI) cost of care, from randomisation to 12 months post-stroke, 
was estimated to be $US6,118 (4,350 to 8,005) per person for control group participants 
compared to $US4,706 (3,758 to 6,014) per person for those who received the Take Charge 
intervention, mean (95%CI) difference $-1,412 (-3,553 to +729) (see Table 1). The main 
differences in resource use for the Take Charge participants compared to the control group 
were a reduction in the rate of acute hospital readmission for stroke; Take Charge 15/270 
(6%) compared to 16/130 (12%) for control; a lower rate of admission to Hospital-level aged 
residential care; Take Charge 1/270 (0.4%) compared to 5/130 (4%) for control; and a lower 
rate of Personal care services; Take Charge 50/270 (19%) compared to control 34/130 (26%).   
Indirect costs were higher for Take Charge participants mainly due to reported higher rates of 
earnings loss; Take Charge 73/270 (27%) compared to control 18/130 (14%). Other direct 
and indirect costs were similar between groups.
The mean quality of life (utility) score for participants in the Take Charge intervention groups 
after one-year was 0.75 (95% CI 0.73 to 0.77) compared to 0.71 (95%CI 0.67 to 0.75) for 
control participants, mean (95%CI) difference 0.04 (0.0 to 0.08). The resulting differences in 
costs, utility and QALYs for the first year are shown in Table 2. The incremental cost-utility 
































































ratio for the first year was $US-35,296(=£-25,524, €-30,019)/QALY, i.e. a net cost-saving 
per QALY gained. Although the mean utility score is higher and mean costs are lower for 
Take Charge participants compared to control, 95% CI for both measures overlap.
The degree of uncertainty in both costs and utility can be explored using microsimulations. 
Figure 2 illustrates the joint distributions of incremental costs and QALY differences derived 
from microsimulations (10,000 replications). The Take Charge intervention was dominant 
(higher utility, lower cost, i.e. ‘south-east’ quadrant) in 92% of the microsimulations for the 
first year.  Cost-effectiveness acceptability curves are another way of considering uncertainty 
of both costs and health utilities. The cost-effectiveness acceptability curve in Figure 3 
suggests that even at a low cost-effectiveness threshold [20, 21], the Take Charge 
intervention is highly likely to be cost-effective. For example, at a willingness to pay 
threshold of $US5,000 per QALY, there is a 99% chance that Take Charge will be cost-
effective from the NZ health funder perspective.
Discussion
The Take Charge session is effective, producing improvements in physical health and 
independence 12 months after stroke [4] and the results from this cost analysis support the 
hypothesis that Take Charge is cost-effective, and probably cost saving.  The incremental 
cost utility ratio comparing Take Charge to control is a negative number, $US-35,296, 
indicating that on average, the control group incurred greater costs than the Take Charge 
group.  Nevertheless the 95% confidence intervals for both QALY and cost difference 
include the possibility that Take Charge is cost-incurring rather than cost-saving.  The main 
contributors to cost saving for Take Charge were a reduction in acute hospital readmission for 
stroke, lower rates of Hospital-level aged residential care and less use of Personal Care 
services.  
































































Take Charge aims to improve a person’s sense of purpose, autonomy, mastery and 
connectedness.[22]  Better connectedness, an improved sense of purpose, as well as improved 
quality of life may explain the trend to lower rates of institutionalisation.  Increased 
autonomy may contribute to lower rates of personal care service use. Autonomy and mastery 
with secondary prevention measures may explain lower rates of hospitalisation for recurrent 
stroke.
The strengths of this study include adequate size, masked outcome assessment, outcomes 
measured 12 months after stroke to ensure sustained response, and excellent follow up rate.  
However, not all those followed up were able to complete the EuroQol-5D-5L, which was 
completed by 340 of the 388 (88%) survivors at 12 months. The frequency of high-cost items 
(rehospitalisation and institutionalisation) were verified by three methods: questionnaire and 
case record review as part of the main data collection process, and Ministry of Health data 
linked to a unique national hospital number for this cost analysis.
Weaknesses of this study include the incomplete cost and EuroQol-5D-5L data from 
questionnaires, and few time points for calculating rehabilitation contact and 
institutionalization. The Taking Charge after Stroke study was carried out in New Zealand, 
which has a publicly funded health service where acute hospital care, early supported 
discharge and community rehabilitation is free to the patient. Costs will necessarily be 
different in other countries.  Nevertheless, the dominance of Take Charge in the sensitivity 
analyses should provide confidence that Take Charge will also be cost-effective in health 
systems very similar to New Zealand, for example Australia, Canada and the United 
Kingdom.  Furthermore, Take Charge is likely to also be cost-effective in broadly similar but 
insurance-based health systems such as the United States, where costs of rehabilitation, 
rehospitalization and Nursing Home admission are borne by the insurer. The low direct costs 
and simplicity of the intervention allow for straightforward implementation.
































































For lower-middle income countries, cost-effectiveness is more difficult to predict. Direct 
costs (primarily salary) are likely to be lower. Better health outcomes would be expected to 
translate into lower health costs for individuals.
We can apply the results from the two randomised trials of Take Charge and this economic 
analysis to a health service providing stroke care to 1,000 new admissions with stroke in one 
year (a catchment population of approximately 600,000 people). Take Charge is appropriate 
for approximately 50% of the incident stroke population: i.e. survivors to non-institutional 
discharge from hospital but not fully recovered. The number needed to treat for one extra 
person to be independent at 12 months is eight. Therefore, for this service, there would be 63 
extra people independent at 12 months, with a one-year cost saving of approximately 
$US700,000 which includes the direct cost of $70,000 for providing two Take Charge 
sessions for 500 people after stroke.  Applying different health perspectives, the person with 
stroke receives a treatment with evidence of meaningful clinical benefit that is in addition to 
guideline-managed acute stroke and rehabilitation and without evidence of harm. The health 
service provides a low-cost treatment, which is easy to implement, benefits patients and may 
lead to fewer readmissions for stroke. The health funder saves money on hospital 
readmissions, Personal Care costs and Hospital-level aged residential care for funding a 
treatment requiring a relatively small increase in the stroke expenditure budget (for this 
example, equivalent to the direct cost of an extra five mechanical thrombectomies [23]) but 
that nevertheless improves health utilities for patients.  
These data strengthen the case for widespread implementation of Take Charge, in addition to 
usual community rehabilitation, for people discharged to community living following stroke. 
































































Take Charge is inexpensive, can be provided to people in their own homes wherever they 
live, and is proven effective in both European-dominant [4] and minority populations. [5] 
Research priorities remaining include determining whether more than two Take Charge 
sessions improve outcomes further, whether earlier intervention (i.e., during hospital 
rehabilitation) is feasible and effective and whether delivery of Take Charge using a virtual 
platform is feasible and effective. 
The effectiveness of Take Charge after stroke should encourage clinicians and researchers to 
develop and test other tools that promote self-rehabilitation and intrinsic motivation, not just 
for people with stroke, but also for people with other conditions requiring rehabilitation.  In 
addition, it provides impetus to rethink how rehabilitation interventions are delivered. We 
need to focus on interventions that are of proven effectiveness for improving important 
outcomes for people with stroke.  This requires incorporating a more psychologically 
informed approach into the current dominant therapy-led rehabilitation paradigm. A first step 
would be to explore explicitly what is most important to the person, identifying what gives 
their life meaning, and anchor therapy and goal setting to that. [24, 25]
Clinical messages:
The Take Charge intervention is cost-effective.
The Take Charge intervention may be cost-saving. In this study the mean (95%CI) cost 
difference (Take Charge minus Control) per participant from randomisation (post hospital 
discharge) until 12 months after stroke was $US-1,412 (-3,553 to +729). 
































































The Take Charge intervention is inexpensive to implement, clinically effective and cost-
effective.  The case for widespread implementation into usual clinical practice is strong.
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Table 1: Cost of all healthcare and non-healthcare resources used and health utility, 
between randomisation (post initial hospital discharge) and 12 months after stroke 
All costs in US dollars
Control 









Programme cost 100% $0  100% $105 102 to 110
       












Community services       
Home help services 44% $1,157
589 to 
2,147 39% $1,430 836 to 2,281






Residential Care 4% $24,709 † 0.4% $24,709 †
Residential home level 
Aged Residential Care 8% $15,962 † 9% $17,957
15,962 to 
23,522






































































Non-health care       
Loss of income 14% $705 513 to 926 27% $543 403 to 735
Informal care cost 18% $864
313 to 
1,700 16% $2,475 547 to 6,096
Total non-health care 
costs 28% $929
545 to 
1499 37% $1,500 616 to 3136






1 year quality adjusted 




N=231 0.75 0.73 to 0.77
*Bootstrap results are based on 1, 000 bootstrap samples. †Sample size too small to allow 
calculation of 95% Confidence Intervals.








































































Take Charge (one or two 
sessions) minus Control
-1,412 (-3,553 to +729) 0.04 (0.0 to 0.08) -35,296
ICUR = incremental cost-utility ratio; QALY = quality adjusted life year
































































Figure 1: CONSORT diagram
Figure 1 Legend: TC1 = one Take Charge session; TC2 = 2 Take Charge sessions
130 were assigned to 
control 
132 were assigned to 
TC 1
138 were assigned to 
TC 2
130 received control 131 received one TC 138 received one TC
3 declined second 
TC session
2 died
133 received two TC
2 died








9 did not return 6m 
questionnaire












3086 patients were assessed for eligibility
   2686  excluded
2255 did not meet inclusion 
criteria
373 declined to participate
58 other (not contactable)
400 underwent 
randomisation
125 included in 
primary analysis
123 included in 
primary analysis
133 included in 
primary analysis
3 did not complete SF-
36 due to cognitive 
impairment
3 did not complete SF-36 
1 declined
2 too unwell
1 did not complete SF-
36 due to cognitive 
impairment
































































Figure 2: Incremental cost effectiveness scatter plot at 12 months
Figure 2: Legend
Scatter plot of estimated joint density of incremental costs and incremental quality-adjusted 
life year (QALY) gained, comparing Take Charge to control. Each dot represents a 
simulation run. Results were obtained from a 10,000 simulation Monte Carlo analysis.
































































Figure 3: Cost effectiveness acceptability curve
Figure 3 Legend: The probability that Take Charge is cost-effective at different thresholds of 
willingness to pay
QALY = quality adjusted life year







































































Items to include when reporting economic evaluations of health interventions 
 
The ISPOR CHEERS Task Force Report, Consolidated Health Economic Evaluation Reporting 
Standards (CHEERS)—Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluations 
Publication Guidelines Good Reporting Practices Task Force, provides examples and further discussion of 
the 24-item CHEERS Checklist and the CHEERS Statement.   It may be accessed via the Value in Health or 







on page No/ 
line No 
Title and abstract 
Title 1 Identify the study as an economic evaluation or use more 
specific terms such as “cost-effectiveness analysis”, and 
describe the interventions compared.  
Abstract 2 Provide a structured summary of objectives, perspective, 
setting, methods (including study design and inputs), results 





3 Provide an explicit statement of the broader context for the 
study. 
 
Present the study question and its relevance for health policy or 
practice decisions.  
Methods 
Target population and 
subgroups 
4 Describe characteristics of the base case population and 
subgroups analysed, including why they were chosen.  
Setting and location 5 State relevant aspects of the system(s) in which the decision(s) 
need(s) to be made.  
Study perspective 6 Describe the perspective of the study and relate this to the 
costs being evaluated.  
Comparators 7 Describe the interventions or strategies being compared and 
state why they were chosen.  
Time horizon 8 State the time horizon(s) over which costs and consequences 
are being evaluated and say why appropriate. 
 
 
Discount rate 9 Report the choice of discount rate(s) used for costs and  
outcomes and say why appropriate.  
Choice of health 
outcomes 
10 Describe what outcomes were used as the measure(s) of 
benefit in the evaluation and their relevance for the type of 
analysis performed.  
Measurement of 
effectiveness 
11a Single study-based estimates: Describe fully the design 
features of the single effectiveness study and why the single 






Method: Measurement of 
health service cost
Method: Interventions
Method: Measurement of 
health service cost
Method: Measurement of 
health service cost
Method: Measurement of 
health utility benefit
Method: study design
Method: Measurement of 
health utility benefit






































































11b Synthesis-based estimates: Describe fully the methods used for 
identification of included studies and synthesis of clinical 
effectiveness data.  
Measurement and 
valuation of preference 
based outcomes 
12 If applicable, describe the population and methods used to 




13a Single study-based economic evaluation: Describe approaches 
used to estimate resource use associated with the alternative 
interventions. Describe primary or secondary research methods 
for valuing each resource item in terms of its unit cost. 
Describe any adjustments made to approximate to opportunity 
costs.  
13b Model-based economic evaluation: Describe approaches and 
data sources used to estimate resource use associated with 
model health states. Describe primary or secondary research 
methods for valuing each resource item in terms of its unit 
cost. Describe any adjustments made to approximate to 
opportunity costs.  
Currency, price date, 
and conversion 
14 Report the dates of the estimated resource quantities and unit 
costs. Describe methods for adjusting estimated unit costs to 
the year of reported costs if necessary. Describe methods for 
converting costs into a common currency base and the 
exchange rate.  
Choice of model 15 Describe and give reasons for the specific type of decision-
analytical model used. Providing a figure to show model 
structure is strongly recommended.  
Assumptions 16 Describe all structural or other assumptions underpinning the 
decision-analytical model.  
Analytical methods 17 Describe all analytical methods supporting the evaluation. This 
could include methods for dealing with skewed, missing, or 
censored data; extrapolation methods; methods for pooling 
data; approaches to validate or make adjustments (such as half 
cycle corrections) to a model; and methods for handling 
population heterogeneity and uncertainty.  
Results 
Study parameters 18 Report the values, ranges, references, and, if used, probability 
distributions for all parameters. Report reasons or sources for 
distributions used to represent uncertainty where appropriate. 
Providing a table to show the input values is strongly 
recommended.  
Incremental costs and 
outcomes 
19 For each intervention, report mean values for the main 
categories of estimated costs and outcomes of interest, as well 
as mean differences between the comparator groups. If 
applicable, report incremental cost-effectiveness ratios.  
Characterising 
uncertainty 
20a Single study-based economic evaluation: Describe the effects 
of sampling uncertainty for the estimated incremental cost and 
incremental effectiveness parameters, together with the impact  
Method: Measurement of 
health utility benefit




















































































of methodological assumptions (such as discount rate, study 
perspective). 
20b Model-based economic evaluation: Describe the effects on the 
results of uncertainty for all input parameters, and uncertainty 
related to the structure of the model and assumptions.  
Characterising 
heterogeneity 
21 If applicable, report differences in costs, outcomes, or cost-
effectiveness that can be explained by variations between 
subgroups of patients with different baseline characteristics or 
other observed variability in effects that are not reducible by 






22 Summarise key study findings and describe how they support 
the conclusions reached. Discuss limitations and the 
generalisability of the findings and how the findings fit with 
current knowledge.  
Other 
Source of funding 23 Describe how the study was funded and the role of the funder 
in the identification, design, conduct, and reporting of the 
analysis. Describe other non-monetary sources of support.  
Conflicts of interest 24 Describe any potential for conflict of interest of study 
contributors in accordance with journal policy. In the absence 
of a journal policy, we recommend authors comply with 
International Committee of Medical Journal Editors 
recommendations.  
 
For consistency, the CHEERS Statement checklist format is based on the format of the CONSORT 
statement checklist 
 
The ISPOR CHEERS Task Force Report provides examples and further discussion of the 24-item 
CHEERS Checklist and the CHEERS Statement.   It may be accessed via the Value in Health link or via the 
ISPOR Health Economic Evaluation Publication Guidelines – CHEERS: Good Reporting Practices 
webpage: http://www.ispor.org/TaskForces/EconomicPubGuidelines.asp 
 
The citation for the CHEERS Task Force Report is: 
Husereau D, Drummond M, Petrou S, et al. Consolidated health economic evaluation reporting standards 
(CHEERS)—Explanation and elaboration: A report of the ISPOR health economic evaluations publication 
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Supplementary Table A: Unit costs used in the cost calculations (2018 New Zealand dollars: 1NZD = 0.7017USD)
Column1 Item Unit  Price or cost per unit Source
 Hospitalisations   NZ dollars  
Hospitalizations Weighted Inlier Equivalent Separations (WIES) National price 2017/2018 cost weight  $          4,921.16 Ministry of Health, New Zealand
Hospitalizations Emergency Department per visit  $             318.24 ADHB Costing
Hospitalizations Intensive Care Unit  per hour  $             186.51 ADHB Costing
Hospitalizations Stroke Unit per day  $             545.03 ADHB Costing
Hospitalizations Neurosurgery Ward Inpatient Ward 6B per day  $             674.06 ADHB Costing Ward 6B
Hospitalizations Neurology ward  (day stay) Per hour  $               47.55 ADHB Costing
Hospitalizations General Ward (Ward 65 – 68) per day  $             509.09 ADHB Costing
Hospitalizations Inpatient Rehabilitation per day  $             593.34 ADHB Costing
Hospitalizations Geriatric A, T & R (active rehabilitation) Awatea, Marino, Rangitoto, Remuera per day  $             452.33 
ADHB Costing (Awatea, Marino, 
Rangitoto, Remuera Wards)
Hospitalizations Outpatient Ward / Day care Per hour  $               34.00 ADHB Costing
Hospitalizations Day hospital, hospital level care Per day  $             192.42 ADHB Costing
 Resthome/Villa Per day  $             124.30 HealthPac
 Number of days in residential (365 days per year /2 [assume 6 months duration]) Number of days 183 Expert opinion
 PHYSIOTHERAPY    
Physiotherapy DHB - Comm Physio FTF FSA per session  $             110.00 ADHB Costing
Physiotherapy DHB - Comm Physio FTF Fup per session  $             110.00 ADHB Costing
Physiotherapy Physiotherapy session per session  $             110.00 ADHB Costing
 OCCUPATIONAL THERAPY    
Occ Therapy Occ Therapy FSA per session  $             100.00 ADHB Costing
Occ Therapy Occ Therapy F/up per session  $             100.00 ADHB Costing
Occ Therapy Occupational therapy (OT01) per session  $             100.00 ADHB Costing
 SPEECH THERAPY    
Speech Therapy Speech Lang Clinic Fup per session  $             130.70 ADHB Costing
Speech Therapy Speech therapy (ST01) per session  $             130.70 ADHB Costing
































































 COUNSELLOR    
Counsellor Psychologist session Per session  $               90.00 ADHB Costing
Counsellor 1.1 Session/Counsel Therapy per session  $               90.00 ADHB Costing
 SOCIAL WORKER    
Social Worker Social Workers FTF FSA per session  $               90.00 ADHB Costing
Social Worker Social Workers FTF FUP per session  $               90.00 ADHB Costing
 NUTRITIONIST OR DIETICIAN    
Nutrition/ Dietician Nutritionist/dietician FSA per session  $               90.00 ADHB Costing
Nutrition/ Dietician Nutritionist/dietician Fup per session  $               90.00 ADHB Costing
 Personal Care    
Personal Care Under 65 years per hour  $               28.00 ADHB/CMDHB Costing
Personal Care Over 65 years per hour  $               28.00 ADHB/CMDHB Costing
 Home Help/Home Management    
Home help Under 65 years per hour  $               22.00 ADHB/CMDHB Costing
Home help Over 65 years per hour  $               22.00 ADHB/CMDHB Costing
ADHB = Auckland District Health Board; CMDHB  = Counties-Manukau District Health Board; FTF = face-to-face; FSA = First specialist assessment; Fup = 
follow up; Comm= community
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